Published online Oct 24, 2023. doi: 10.5306/wjco.v14.i10.373
Peer-review started: July 30, 2023
First decision: August 24, 2023
Revised: September 7, 2023
Accepted: September 18, 2023
Article in press: September 18, 2023
Published online: October 24, 2023
Processing time: 85 Days and 17.5 Hours
Gastric cancer (GC) is one of the most common malignant tumors, although its pathogenesis remains unclear.
For the first time, in the current study, we constructed a new GC prognostic model based on the sub-group analysis of disulfidptosis-related genes (DRGs) and explored treatment targets and sensitive drugs.
The aims of this study were to explore a new GC prognostic model based on the sub-group analysis of DRGs and explore treatment targets and sensitive drugs.
In this study, a bioinformatics strategy was used to extract GC-related data from The Cancer Genome Atlas and Gene Expression Omnibus databases, while R software (version 4.2.1) was used for correlation analysis.
Through the above analysis, we found that the didisulfidptosis-related gene may be related to the prognosis of GC. Six genes, namely, PLS3, GRP, APOD, SGCE, COL8A1, and VAMP7, constitute a predictive model for GC prognosis. APOD is a potential therapeutic target. Bosutinib and other drugs are suitable for the treatment of GC.
The results of this study indicate that didisulfidptosis is related to the prognosis and treatment of GC. Additionally, APOD can be used as a potential therapeutic target for GC.
Six genes, namely, PLS3, GRP, APOD, SGCE, COL8A1, and VAMP7, constitute a predictive model for GC prognosis. APOD is a potential therapeutic target for treating GC. Bosutinib and other drugs are suitable for the treatment of GC, although this requires further confirmation through molecular biology and clinical experiments.